Poster Presentations

Our Data Presented

We benefit greatly from ongoing discussions of our data with the medical and public health communities.
Our posters facilitate these discussions by highlighting key data for presentation at global conferences.

PosterDetailsCategoryRelateddoc_categories_hfilter
Lower non-response rates to 3-antigen HBV vaccine among adults with diabetes, age ≥ 45, or obesity compared to a single-antigen HBV vaccine: PROTECT STUDY

Lower non-response rates to 3-antigen HBV vaccine among adults with diabetes, age ≥ 45, or obesity compared to a single-antigen HBV vaccine: PROTECT STUDY

Conference: American Diabetes Association’s Virtual 81st Scientific Sessions
Date: June 25, 2021

View Press Releasehepatitis-b
Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study

Restoration of HBV-specific immune responses with therapeutic vaccine BRII-179 (VBI-2601) in chronic HBV patients in a phase 1b/2a study

Conference: Annual Meeting of the European Association for the Study of the Liver (EASL) 2021
Date: June 23, 2021

View Press Releasehepatitis-b
A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine

A 3-antigen prophylactic hepatitis B virus vaccine confers rapid onset of protection in young adults, age 18-45, compared to a single-antigen hepatitis B virus vaccine

Conference: Annual Meeting of the European Association for the Study of the Liver (EASL) 2021
Date: June 23, 2021

View Press Releasehepatitis-b
Robust Immunogenicity and Rapid Onset of High Rates of Seroprotection and Anti-HBs Titers, Elicited with 3-Antigen Hepatitis B Vaccine in Adults

Robust Immunogenicity and Rapid Onset of High Rates of Seroprotection and Anti-HBs Titers, Elicited with 3-Antigen Hepatitis B Vaccine in Adults

Conference: 2021 International Symposium on Viral Hepatitis and Liver Disease (ISVHLD)
Date: June 18, 2021

View Press Releasehepatitis-b
Evaluation of GM-CSF and AS01B Adjuvants in a Phase I/IIa Trial of a Therapeutic CMV Vaccine (VBI-1901) Against Recurrent Glioblastoma (GBM)

Evaluation of GM-CSF and AS01B Adjuvants in a Phase I/IIa Trial of a Therapeutic CMV Vaccine (VBI-1901) Against Recurrent Glioblastoma (GBM)

Conference: 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Date: June 8, 2021

View Press Releaseglioblastoma
Higher seroprotection rates (SPR) and higher anti-HBs concentrations in adults age 18-45 immunized with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal, double-blind, randomized Phase 3 study (CONSTANT)

Higher seroprotection rates (SPR) and higher anti-HBs concentrations in adults age 18-45 immunized with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal, double-blind, randomized Phase 3 study (CONSTANT)

Conference: Canadian Liver Meeting 2021
Date: May 5, 2021

View Press Releasehepatitis-b
Identification of a baseline biomarker associated with tumor responses in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Identification of a baseline biomarker associated with tumor responses in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Conference: 2020 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: November 19, 2020

View Press Release

Watch Video
glioblastoma
A 3-antigen hepatitis B vaccine provides consistently higher seroprotection rates (SPR) and anti-HBs titers compared to single-antigen vaccine in adults with comorbidities known to be associated with poor response to vaccinations: Results from the phase III double-blind, randomized study (PROTECT)

A 3-antigen hepatitis B vaccine provides consistently higher seroprotection rates (SPR) and anti-HBs titers compared to single-antigen vaccine in adults with comorbidities known to be associated with poor response to vaccinations: Results from the phase III double-blind, randomized study (PROTECT)

Conference: American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2020
Date: November 13, 2020

View Press Releasehepatitis-b
Rapid onset of seroprotection rates in young adults immunized with a 3-antigen hepatitis B virus (HBV) vaccine compared to a single-antigen HBV vaccine

Rapid onset of seroprotection rates in young adults immunized with a 3-antigen hepatitis B virus (HBV) vaccine compared to a single-antigen HBV vaccine

Conference: IDWeek 2020™
Date: October 26, 2020

View Press Releasehepatitis-b
Higher hepatitis B antibody titers induced in all adults vaccinated with a 3-antigen hepatitis B (HBV) vaccine, compared to a single-antigen HBV vaccine: Results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT)

Higher hepatitis B antibody titers induced in all adults vaccinated with a 3-antigen hepatitis B (HBV) vaccine, compared to a single-antigen HBV vaccine: Results from two pivotal phase 3 double-blind, randomized studies (PROTECT and CONSTANT)

Conference: IDWeek 2020™
Date: October 26, 2020

View Press Releasehepatitis-b
TCR and HLA analysis of patients in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (rGBM)

TCR and HLA analysis of patients in a Phase I/Iia trial of a therapeutic CMV vaccine against recurrent glioblastoma (rGBM)

Conference: The European Society for Medical Oncology (ESMO) Virtual Congress 2020
Date: September 17, 2020

View Press Releaseglioblastoma
Higher proportion of responders with hepatitis B antibody levels ≥ 100 mIU/mL with the tri-antigenic HepB vaccine, Sci-B-Vac®, compared to Engerix-B®: Results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)

Higher proportion of responders with hepatitis B antibody levels ≥ 100 mIU/mL with the tri-antigenic HepB vaccine, Sci-B-Vac®, compared to Engerix-B®: Results from the phase 3 double-blind, randomized study comparing immunogenicity and safety (PROTECT)

Conference: The Digital International Liver Congress™ 2020 (ILC) - the Annual Meeting of the European Association for the Study of the Liver (EASL)
Date: August 31, 2020

View Press Releasehepatitis-b
CMV-specific immuno-dyregulation in recurrent glioblastoma patients can be overcome with therapeutic vaccineation which is associated with tumor response and overall survival benefits in a Phase I/Iia study

CMV-specific immuno-dyregulation in recurrent glioblastoma patients can be overcome with therapeutic vaccineation which is associated with tumor response and overall survival benefits in a Phase I/Iia study

Conference: 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Date: June 22, 2020

View Press Release

Watch Video
glioblastoma
Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Interim results of the extension phase of a Phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)

Conference: 2019 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: November 22, 2019

View Press Releaseglioblastoma
Rapid increase in anti-HBsAg titers and higher seroprotection rates in adults immunized with Sci-B-Vac® compared to a monovalent hepatitis B vaccine: Results from PROTECT - a double-blind, randomized, controlled, Phase 3 study

Rapid increase in anti-HBsAg titers and higher seroprotection rates in adults immunized with Sci-B-Vac® compared to a monovalent hepatitis B vaccine: Results from PROTECT - a double-blind, randomized, controlled, Phase 3 study

Conference: American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2019
Date: October 22, 2019

View Press Releasehepatitis-b
CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

Conference: 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Date: June 4, 2019

View Press Releaseglioblastoma
High seroprotection rates achieved with two doses of Sci-B-Vac, a third-generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens

High seroprotection rates achieved with two doses of Sci-B-Vac, a third-generation hepatitis B vaccine containing Pre-S1, Pre-S2, and S antigens

Conference: 2019 Annual Meeting of the European Association for the Study of the Liver (EASL)
Date: April 9, 2019

View Press Releasehepatitis-b
CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

CMV gB/pp65 eVLPs formulated with GM-CSF as a therapeutic vaccine against recurrent GBM

Conference: 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
Date: October 24, 2018

View Press Releaseglioblastoma

Sign-up for Our Distribution List to Receive the Latest News and Updates from VBI

Sign Up Now for our newsletterArrow
Go top